Subcutaneous Enoxaparin for Systemic Anticoagulation of COVID-19 Patients During Extracorporeal Life Support
BackgroundExtracorporeal membrane oxygenation, with an inherent requirement for anticoagulation to avoid circuit thrombosis, is a key element in the treatment of respiratory failure associated with COVID-19. Anticoagulation remains challenging, the standard of care being intravenous continuous admin...
Main Authors: | Marion Wiegele, Daniel Laxar, Eva Schaden, Andreas Baierl, Mathias Maleczek, Paul Knöbl, Martina Hermann, Alexander Hermann, Christian Zauner, Johannes Gratz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.879425/full |
Similar Items
-
Monitoring of Enoxaparin during Hemodialysis Covered by Regional Citrate Anticoagulation in Acute Kidney Injury: A Prospective Cohort Study
by: Marion Wiegele, et al.
Published: (2021-09-01) -
Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy
by: Daniel Laxar, et al.
Published: (2023-04-01) -
Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children
by: Madhuradhar Chegondi, et al.
Published: (2022-07-01) -
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report
by: Miroslav Durila, et al.
Published: (2023-04-01) -
Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome
by: Adisak Weerasaksanti, et al.
Published: (2023-05-01)